Rarity PBC Closes $4.6M Seed Round to Advance Gene Therapy for ADA-SCID

Why It Matters

The funding backs a potentially curative therapy for a life‑threatening rare disease, accelerating its path to market and underscoring investor confidence in biotech ventures structured as public benefit corporations.

Deal Summary

Rarity PBC announced the closing of a $4.6M seed financing led by biotech investor Steve Oliveira of Nemean Asset Management to accelerate development of its autologous hematopoietic stem cell gene therapy for ADA-SCID.